Introduction: Acromegaly, a chronic disease caused by GH/IGF-I excess, has a major impact on quality of life (QoL). Objective: To evaluate QoL of acromegalic patients in relation to control status of the disease. Design and methods: Single center observational study including 93 patients with acromegaly recruited to complete QoL questionnaire (AcroQol). QoL was evaluated at least 3 months after surgery and/or medical treatment. Patients were divided into two groups: controlled (I) and uncontrolled (II) according to the latest consensus acromegaly 'control' criteria and further subdivided into four subgroups according to the previous pituitary adenoma surgery (Ib and IIb) or without surgery (Ia and IIa). Results: Mean GH (0.81G0.47 ng/ml) and IGF-I (195G71 ng/ml) values in group I were significantly lower than in group II (GH, 7.01G12.05 ng/ml and IGF-I, 513G316 ng/ml; P!0.001). There was no difference in total AcroQol score, physical, or psychological scales between groups I and II. However, when adjusted to age and disease duration since diagnosis, patients of group I (63G20%) showed an improved psychological subscale appearance than those of group II (58G17%; PZ0.035). In group II, IGF-I level was lower after surgery (IIaZ588G353, IIbZ410G225 ng/ml; P!0.038), and psychological subscale appearance was significantly better in subgroup IIb (64.9G18.1%) than in subgroup IIa who had medical treatment (53.9G14.3%; PZ0.009). Conclusion: QoL is severely impaired in acromegalic patients. Control of GH/IGF-I excess by surgery or medical treatment seems to have a positive impact on psychological subscale appearance.

No abstract

As the first demonstration of the insulin-sensitizing action of apelin in humans, alongside numerous studies in rodents, this trial confirms that the apelin/APJ pathway should be considered as a new target to design alternative therapeutic strategies to control insulin resistance in type 2 diabetic patients.

This study is the first to describe CGM profile in pregnant women after RYGB. CGM features are similar to those of non-pregnant post-RYGB patients, characterized by wide and rapid changes in postprandial IG, and high exposure to hyperglycemia. The exposure to hyperglycemia is similar to what is reported in GDM although the time to postprandial peak is shorter. CGM could be an additional useful approach to screen for glucose intolerance during pregnancy after RYGB.